Zhejiang Hisun Pharmaceutical's (SHA:600267) unit, Zhejiang Hisun Animal Health Products, received a veterinary drug registration certificate for fenbendazole oral suspension from China's Ministry of Agriculture and Rural Affairs, according to a Tuesday filing on the Shanghai Stock Exchange.
The drug is intended to treat animals with worms such as, ascaris suum, oesophagostomum nematodes and Whipworms, the Tuesday disclosure added.
Price (RMB): ¥7.63, Change: ¥+0.05, Percent Change: +0.66%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments